TrialX
Image

Multi-dimensional Evaluation System for Recanalization of Symptomatic Non-acute Carotid Artery Occlusion

Multi-dimensional Evaluation System for Recanalization of Symptomatic Non-acute Carotid Artery Occlusion

Recruiting
18-80 years
All
Phase N/A

Overview

This is a multi-center, prospective, exploratory, observational, registration study on patients with symptomatic non-acute carotid artery occlusion to initially evaluate the safety and efficacy of endovascular treatment.

Description

Although patients with symptomatic carotid occlusion were primarily treated with medication, the risk of 2-year stroke recurrence was as high as 22.7%. Ipsilateral stroke and hemodynamic decline are independent risk factors for stroke recurrence in patients with carotid artery occlusion. In addition, long-term cerebral hypoperfusion and decreased cerebrovascular reactivity in patients with carotid artery occlusion may lead to cognitive impairment.

At present, the recanalization time window of anterior circulation large vessel occlusive stroke has been extended to 24 hours under certain evaluation approaches. In order to distinguish from the emergency treatment within 24 hours, patients with carotid artery occlusion over 24 hours are collectively referred as non-acute occlusion.

With the maturity of endovascular technique and the advances of interventional devices, endovascular treatment has become a hotspot of clinical research in this field. Case reports have emerged and prospective studies suggest that recanalization of chronic carotid occlusion may improve the cognitive functions. However, the clinical benefit of endovascular treatment for symptomatic non-acute carotid artery occlusion remained controversial.

The purpose of this study is to establish and verify the efficacy of a multi-dimensional evaluation system of endovascular treatment and recanalization of symptomatic non-acute carotid occlusion.

Eligibility

Inclusion Criteria:

  1. Sign the informed consent form
  2. Age: 18-80 years old;
  3. Occlusion of the common carotid artery or internal carotid artery (TICI=0) confirmed by DSA
  4. The origin of occlusive segment is from the common carotid artery or the initial segment of the internal carotid artery to the petrous segment and above, and does not exceed the bifurcation of the internal carotid artery (C7 segment). The distal occluded vessels, including the middle cerebral artery, have no severe stenosis or occlusion confirmed by angiography
  5. Occlusion over 24 hours (confirmed by imaging or according to the patient's condition change)
  6. Ischemic stroke, TIA or progressive visual impairment associated with occlusion
  7. Small infarct showed by CT or MR examination (the maximum diameter of single infarct area 3cm), large hypoperfusion area indicated by CT perfusion (quantitative analysis with e-stroke software)
  8. No severe neurological dysfunction (NIHSS 8 or Mrs 3) before procedure

Exclusion Criteria:

  1. Non-atherosclerotic occlusion (such as vasculitis, moyamoya disease, etc.)
  2. Evidence of cardiogenic embolism
  3. Allergic to heparin, aspirin, clopidogrel, statins, metals and anesthetics, or intolerant to general anesthesia
  4. History of serious allergy to contrast media (excluding rash)
  5. Untreated intracranial aneurysms, intracranial tumors (other than meningiomas) or any intracranial vascular malformations
  6. Any history of intracranial hemorrhage (including cerebral parenchyma, ventricles, subarachnoid hemorrhage, subdural or extradural hemorrhage) within 30 days
  7. History of primary cerebral parenchymal hemorrhage
  8. Recent history of gastrointestinal bleeding with intolerance with antiplatelet therapy
  9. Active bleeding constitution or coagulation disease, active peptic ulcer disease, systemic bleeding within 30 days, platelet count < 100 109 / L, hemoglobin < 9g / L, INR > 1.5, bleeding time more than the upper limit of normal value for 1 min, heparin-associated thrombocytopenia increases the risk of bleeding
  10. Uncontrolled severe hypertension (systolic blood pressure > 180mmhg or diastolic blood pressure > 110mmhg)
  11. Severe coronary heart disease, severe liver injury (AST or ALT more than 3 times of normal value), cirrhosis and severe renal insufficiency (creatinine > 177 mol / L)
  12. Major surgery within 30 days or within the next 90 days
  13. Known to have dementia or mental illness, and unable to complete neurological and cognitive assessment
  14. Expected survival time1 year due to other diseases
  15. Pregnant or lactating female
  16. Included in other studies and in conflict with this study
  17. Other special circumstances not suitable for endovascular surgery by consideration of neuro-physician, neurosurgeon, or neurointerventional

Study details
    Carotid Artery Occlusion

NCT04291430

Beijing Tiantan Hospital

16 February 2024

Step 1 Get in touch with the nearest study center
Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team


Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.